Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00121680 · ClinicalTrials.gov registry record · Phase 1
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
A Phase 1 study of Metastatic Melanoma, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 115
- Enrollment target
- 2
- Study locations
NCT00121680 is a Phase 1 study of Metastatic Melanoma that has completed, run by Eisai. The registered enrollment target is 115 participants, above the 82-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (40% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT00121680, a Phase 1 study of Metastatic Melanoma, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 115 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to study the safety of E7080 administered to patients with solid tumors or lymphomas. Please note: this study is now recruiting patients with advanced and/or metastatic melanoma only. In the current phase of this study, To determine the MTD and the pharmacokinetic profile of E7080 when given as continuous daily (qd) dosing in combination with temozolomide.
Conditions Studied
Interventions
- DRUG E7080
Study Locations (2)
Texas
- - Dallas
- - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2005-07 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00121680
The ClinicalTrials.gov registry entry for NCT00121680 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 82-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (40% higher). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Melanoma appearing as the primary indexed condition, and to 1 intervention - of which E7080 is the first listed.
NCT00121680 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00121680 about?
NCT00121680 is a clinical study titled "A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma". The purpose of this study is to study the safety of E7080 administered to patients with solid tumors or lymphomas. Please note: this study is now recruiting patients with advanced and/or metastatic melanoma only. In the current phase of this study, To determine the MTD and the pharmacokinetic prof...
What is the current status of trial NCT00121680?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 115 participants. The study started on 2005-07. Estimated completion is 2015-05.
What conditions does trial NCT00121680 study?
This clinical trial studies the following conditions: Metastatic Melanoma.
What interventions are being tested in trial NCT00121680?
The interventions under investigation include: E7080 (DRUG).
Who is sponsoring clinical trial NCT00121680?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00121680 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
RECRUITING · Phase 1
-
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
RECRUITING · Phase 1
-
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
RECRUITING · Phase 1
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.